Technical Analysis for CALA - Catalina Lighting

Grade Last Price % Change Price Change
D 0.0500 0.00% 0.0000
CALA closed down 16.67 percent on Friday, March 17, 2023, on 5 percent of normal volume.

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Extremely Strong N/A N/A Down

Date Alert Name Type % Chg
Narrow Range Bar Range Contraction 0.00%
Doji - Bullish? Reversal 0.00%
Wide Bands Range Expansion 0.00%
Gapped Down Weakness 0.00%
Hot IPO Pullback Bullish Swing Setup -16.67%
Pocket Pivot Bullish Swing Setup -16.67%
Wide Bands Range Expansion -16.67%
Gapped Up Strength -16.67%
Oversold Stochastic Weakness -16.67%
Wide Bands Range Expansion -1.96%

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
Down 10% 43 minutes ago
Down 5% 43 minutes ago
Down 3% 43 minutes ago
Down 1% 43 minutes ago
Down 2% 43 minutes ago

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.


Catalina Lighting Description

Calithera Biosciences, Inc., a clinical-stage bio-pharmaceutical company, focuses on the discovery and development of small molecule compounds for tumor metabolism and tumor immunology targets for the treatment of cancer in the United States. The company offers INCB001158, an orally bioavailable arginase inhibitor of arginase that is in Phase 1/2 clinical trial for the treatment of hematology and oncology. It is developing CB-280, an oral arginase inhibitor that has completed Phase 1b clinical trial for the treatment of cystic fibrosis and chronic airway infection; and ATG-037, an orally-bioavailable small molecule inhibitor of CD73, as well as CB-668, an orally administered inhibitor of the enzyme IL4I1. The company has a license agreement with Mars, Inc. to develop and commercialize Symbioscience's portfolio of arginase inhibitors for use in human healthcare. It also has clinical trial collaboration with Pfizer to evaluate Pfizer's PARP inhibitor talazoparib and CDK4/6 inhibitor palbociclib, each in combination with telaglenasta. In addition, the company has a collaboration and license agreement with Incyte Corporation for the research, development, and commercialization of INCB001158, a small molecule arginase inhibitor for the treatment of hematology and oncology; and a license agreement with Antengene Corporation Ltd. for the development and commercialization of CB-708. Calithera Biosciences, Inc. was incorporated in 2010 and is headquartered in South San Francisco, California.


Sector: Healthcare
Industry: Biotechnology
Keywords: Cancer Organic Compounds Chemical Compounds Treatment Of Cancer Tumor Bio Pharmaceutical Cystic Fibrosis Lactams Breakthrough Therapy Parp Inhibitors Piperazines Protein Kinase Inhibitors Treatment Of Cystic Fibrosis

Is CALA a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength


Indicator Value
52 Week High 0.34
52 Week Low 0.045
Average Volume 128,731
200-Day Moving Average 0.0000
50-Day Moving Average 0.0000
20-Day Moving Average 0.0631
10-Day Moving Average 0.0535
Average True Range 0.0230
RSI 31.03
ADX 78.44
+DI 2.4899
-DI 16.2776
Chandelier Exit (Long, 3 ATRs) 0.0400
Chandelier Exit (Short, 3 ATRs) 0.1140
Upper Bollinger Bands 0.0926
Lower Bollinger Band 0.0336
Percent B (%b) 0.28
BandWidth 93.5024
MACD Line -0.0187
MACD Signal Line -0.0202
MACD Histogram 0.0015
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 0.0650
Resistance 3 (R3) 0.0667 0.0633 0.0625
Resistance 2 (R2) 0.0633 0.0595 0.0625 0.0617
Resistance 1 (R1) 0.0567 0.0572 0.0550 0.0550 0.0608
Pivot Point 0.0533 0.0533 0.0525 0.0525 0.0533
Support 1 (S1) 0.0467 0.0495 0.0450 0.0450 0.0392
Support 2 (S2) 0.0433 0.0472 0.0425 0.0383
Support 3 (S3) 0.0367 0.0433 0.0375
Support 4 (S4) 0.0350